Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 42, Issue 10, 2008, Pages 649-657

  Damon, L ^a   Damon, L E ^a   Gaensler, K ^a   Kaplan, L ^a   Martin III, T ^a   Rubenstein, J ^a   Linker, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARBOPLATIN; CARMUSTINE; CISPLATIN; COMPLEMENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; T LYMPHOCYTE ANTIBODY; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOMYOPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEM CELL MOBILIZATION; TOXICITY TESTING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CYTARABINE; ETOPOSIDE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57049135254     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.236     Document Type: Article

References (24)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Damon L, Rugo H, Tolaney S, Navarro W, Martin III T, Ries C et al. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316-324.
3. Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000; 6: 50-57.
4. Damon L, Johnson J, Niedzwiecki D, Cheson BD, Hurd D, Bartlett N et al. Immuno-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909. Blood 2006; 108: 774a (abst 2737).
5. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schrober JR, Chao NJ, Long GD et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 3334-3341.
6. Negrin RS, Kiem HP, Schmidt-Wolf IG, Blume KG, Clearly ML. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77: 654-660.
7. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-632.
8. Arcaini L, Orlandi E, Alessandrino EP, Iacono I, Brusamolino E, Bonfichi M et al. A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34: 175-179.
9. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modi.cation reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15: 833-839.
10. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76-85.
11. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Guliotta L, Tognani G et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-1875.
12. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing highdose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 387-394.
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
14. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D et al Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
15. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB. Recent advances in the application of gene therapy to human disease. Am J Med 1995; 99: 537-552.
16. Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 32: 279-288.
17. Alici E, Björkstrand B, Treschow A, Aints A, Smith CI, Gahrton G et al. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther 2007; 14: 227-232.
18. Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 747-755.
19. Ballestrero A, Clavio M, Ferrando F, Gonella R, Garuti A, Sessarego M et al. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol 2000; 17: 1007-1013.
20. Haioun C, Mounier N, Quesnel B, Morel P, Rieux C, Beaujen F et al. Tandem autotransplant as, first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. Ann Oncol 2001; 12: 1749-1755.
21. Le Gouill S, Moreau P, Morineau N, Harousseau JL, Milpied N. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: A prospective pilot study. Haematologica 2002; 87: 333-334.
22. Ahmed T, Rashid K, Waheed F, Kancherla R, Qureshi Z, Hoang A et al Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma 2005; 46: 405-414.
23. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J et al Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol 2005; 84: 517-525.
24. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL et al. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant 2005; 36: 491-497.